About Us

Overview

Urologix, Inc., based in Minneapolis, Minnesota develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. Urologix has developed and offers non-surgical, catheter-based treatments that use proprietary microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix is a leader in less invasive technology for the treatment of BPH, with more than 200,000¹ patients treated to date.

Urologix' patented Cooled ThermoTherapy™ technology is creating effective² treatment options for a wide range of patients with BPH. Cooled ThermoTherapy technology delivers precisely targeted microwave energy that heats and destroys enlarged prostatic tissue while unique cooling mechanisms protect surrounding healthy tissue and enhances patient comfort.

Urologix' stock is traded on NASDAQ under the symbol ULGX. The company is focused on product development, expansion of its fast-growing mobile service and crossing borders internationally with distribution partners in India, Taiwan and the People's Republic of China.

¹Data on file at Urologix, Inc.
²Miller, Paul D., et al, Cooled ThermoTherapy for the Treatment of Benign Prostatic Hyperplasia: Durability of Results Obtained with the Targis System, Urology, Vol. 61, No. 6, June 2003.

Milestones

1991

• Urologix^® is founded to develop manufacture and market medical devices for the treatment of urological disorders

1997

• Urologix' first product, the Targis^® Cooled TUMT System, is approved by the FDA as a safe, durable, minimally invasive treatment alternative to drugs and surgery for the treatment of BPH

1999

• Cruise software update including automated urethral feedback introduced

2000

• Urologix purchases the Prostatron^® Cooled TUMT System
• Cruise II software update with enhanced rectal temperature feedback preventing unnecessary system shut downs introduced
• Shorter treatment time (28.5 minutes) approved

2002

• Targis Microwave Catheter [Short] introduced

2003

• Targis Microwave Catheter [Long] introduced
• Cooled ThermoCath^® (CTC) [Standard] Microwave Catheter receives FDA approval
• Rectal Thermal Unit Plus offered

2005

• Urologix acquires three regional mobile BPH treatment service providers and launched its Urologix Mobile™ Service
• Cooled ThermoCath (CTC) [Long] Microwave Catheter receives FDA approval

2006

• The CoolWave^® Control Unit enabling urologists to further customize BPH treatments for individual patients, is approved by the FDA and released to the marketplace

2007

• Developed software upgrade for Targis System
• Began CTC Advance™ Microwave Catheter* development

2008

• CTC Advance™ Microwave Catheter receives FDA approval
• 5 Year results for Cooled ThermoTherapy™ presented at AUA, Continuing Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH

Board of Directors

Mitchell Dann	Chairman and Interim CEO Urologix, Inc.
Daniel J. Starks	Chairman, President & Chief Executive Officer St. Jude Medical, Inc.
Guy C. Jackson	Former Partner Ernst & Young LLP
Sidney W. Emery, Jr.	Chairman MTS Systems Corporation
Jerry C. Cirino	Chief Executive Officer Heartland Information Services
William M. Moore	Consultant Blueline Partners

Leadership Team

Mitchell Dann	Chairman and Interim CEO
Kirsten Doerfert	Senior Vice President & General Manager
Rebecca J. Weber	Director of Finance & Controller
Jonathan Achenbach	Sr. Director of Product Development
Roger Martin	Director of Operations
Jennifer Willner	Director of Regulatory & Quality
Sara Thompson	Director of Marketing

Media Room

Welcome to Urologix’ Media Room, the resource for up-to-date Cooled ThermoTherapy™ branded press releases, high-resolution images and current fact sheets. If you would like to download these materials, we ask that you fill out a brief form.

Urologix Fact Sheet

Urologix Mobile Fact Sheet

Cooled ThermoTherapy Fact Sheet

Cooled ThermoTherapy FAQs